Mersana Therapeutics, Inc. MRSN was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.16 to $7.61 in the past one-month time frame.
The company has seen a mixed track record when it comes to estimate revision of no increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Mersana Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Mersana Therapeutics, Inc. Price
Mersana Therapeutics, Inc. price | Mersana Therapeutics, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Alexion Pharmaceuticals, Inc. ALXN, which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is MRSN going up? Or down? Predict to see what others think:Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research